Every Form 4 that Traws Pharma, Inc. (TRAW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TRAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAW filings page.
Traws Pharma, Inc. reported a compensation-related insider transaction for Chief Science Officer Virology Charles David Pauza. He received a grant of 97,000 stock options on July 9, 2026, with an exercise price of $0.68 per share, vesting 100% on July 9, 2027 and expiring July 9, 2036. Following the award, he directly holds options for 97,000 underlying shares of common stock.
Traws Pharma, Inc. director Werner Cautreels received a grant of stock options to acquire 14,150 shares of common stock at an exercise price of $0.68 per share. The options, granted on July 9, 2026 under the 2021 Incentive Compensation Plan, vest 100% after one year and expire on July 9, 2036, leaving him holding options for 14,150 shares directly.
Traws Pharma, Inc. reported that Chief Operating Officer Nikolay Savchuk received a grant of stock options covering 93,000 shares of common stock on July 9, 2026. The options have an exercise price of $0.68 per share, expire on July 9, 2036, and vest 100% on the first anniversary of the grant date.
Traws Pharma, Inc. director Jack E. Stover received a grant of stock options for 14,150 shares of common stock on July 9, 2026. The options have a $0.68 exercise price, were awarded under the 2021 Incentive Compensation Plan, and were granted at $0.00 per option as compensation. They vest 100% on the first anniversary of the grant date and expire on July 9, 2036. Following this award, Stover directly holds options covering 14,150 shares.
Traws Pharma, Inc. granted its Chief Executive Officer and director, Iain D. Dukes, stock options covering 274,000 shares of common stock with an exercise price of $0.68 per share under its 2021 Incentive Compensation Plan.
The options vest 100% on the first anniversary of the July 9, 2026 grant date and expire on July 9, 2036, leaving Dukes holding 274,000 options following this award.
Traws Pharma, Inc. granted Chief Medical Officer Robert Redfield a stock option award covering 84,000 shares of common stock. The options have an exercise price of $0.68 per share and expire on 2036-07-09. The award was granted at a transaction price of $0.00 per option under the company’s 2021 Incentive Compensation Plan, as amended. According to the award terms, the options will vest 100% on the first anniversary of the 2026-07-09 grant date. Following this grant, Redfield directly holds options for 84,000 underlying shares.
Traws Pharma, Inc. reported that Chief Financial Officer Parker Charles Nolan received a grant of 90,000 stock options to purchase common stock. The options have an exercise price of $0.68 per share, vest 100% on the first anniversary of the July 9, 2026 grant date, and expire on July 9, 2036. The award was approved by the compensation committee of independent directors under the company’s 2021 Incentive Compensation Plan. Following this grant, Nolan holds 90,000 stock options directly.
Traws Pharma director Mary Teresa Shoemaker received a grant of stock options for 14,150 shares of common stock on July 9, 2026 at an exercise price of $0.68 per share. Granted under the 2021 Incentive Compensation Plan, the options vest 100% on the first anniversary of the grant date and expire on July 9, 2036, and are held directly.
Traws Pharma, Inc. director Clarke Trafford received a grant of stock options to purchase 14,150 shares of common stock at an exercise price of $0.68 per share. The options were awarded under the company’s 2021 Incentive Compensation Plan, vest 100% one year after the grant date, and expire on July 9, 2036, leaving Trafford with 14,150 options following the award.
Traws Pharma, Inc. director John Harold Leaman received a grant of 14,150 stock options to buy common stock at an exercise price of $0.6800 per share. Granted under the 2021 Incentive Compensation Plan, these options vest 100% on July 9, 2027 and expire on July 9, 2036, leaving Leaman holding 14,150 derivative securities directly.
Entities affiliated with OrbiMed increased their indirect stake in Traw Pharma through a private placement. OrbiMed Private Investments VIII LP acquired 597,729 shares of common stock at $1.67 per share and Series A, B and C warrants exercisable for up to 2,988,645 shares at $1.673 per share. Following the purchase, indirect holdings reported for common stock rose to 1,203,250 shares. The transactions closed on April 16, 2026, and the reporting entities disclaim beneficial ownership beyond their pecuniary interest.
Parker Charles Nolan reported acquisition or exercise transactions in this Form 4 filing.
Traws Pharma, Inc. Chief Financial Officer Parker Charles Nolan reported multiple equity awards from the company. He received 15,393 restricted stock units that vest 100% on the first anniversary of the grant date. He was also granted stock options for 104,544 shares at $1.60, 61,571 shares at $2.33, and 32,406 shares at $3.01 per share, each vesting in full one year after the respective grant dates.
Traws Pharma director Clarke Trafford received a new stock option grant as part of his compensation. He was awarded options for 33,435 shares of common stock at an exercise price of $1.60 per share. These options were granted under the company’s 2021 Incentive Compensation Plan by the independent compensation committee and will vest 100% on the first anniversary of the March 8, 2026 grant date. Following this award, Trafford holds 33,435 stock options directly, which are scheduled to expire on March 8, 2036.
Traws Pharma, Inc. director Werner Cautreels received a grant of stock options as compensation. He was awarded 31,258 options to buy common stock at an exercise price of $1.6000 per share. These options vest 100% on the first anniversary of the March 8, 2026 grant, and his reported derivative holdings after the grant are 31,258 options.
Traws Pharma director John Harold Leaman received a stock option grant for 33,435 shares of common stock. The options have an exercise price of $1.60 per share and were awarded at no upfront cost as compensation. According to the award terms, the options will vest 100% on the first anniversary of the March 8, 2026 grant date, after which they become exercisable. Following this grant, Leaman holds 33,435 stock options directly.
Traws Pharma, Inc. granted Chief Executive Officer Iain D. Dukes stock options covering 231,336 shares of common stock. The options have a $1.60 exercise price, were awarded at no cost, and will vest 100% on the first anniversary of the March 8, 2026 grant date. They expire on March 8, 2036 and represent compensation approved by the company’s independent compensation committee under its 2021 Incentive Compensation Plan, rather than an open-market share purchase or sale.
Traws Pharma, Inc. reported that Chief Science Officer Virology Charles David Pauza received a grant of 118,367 stock options to buy common stock at an exercise price of $1.6000 per share. These options were awarded by the compensation committee under the company’s 2021 Incentive Compensation Plan and will vest 100% on the first anniversary of the March 8, 2026 grant date. Following this award, Pauza holds 118,367 options directly, and the options are scheduled to expire on March 8, 2036.
Traws Pharma, Inc. reported that its Chief Operating Officer, Nikolay Savchuk, received a grant of stock options as part of his compensation. He was awarded 96,899 stock options to buy common shares at an exercise price of $1.60 per share, expiring on March 8, 2036. These options were granted under the company’s 2021 Incentive Compensation Plan and will vest 100% on the first anniversary of the grant date, meaning they become fully exercisable after one year. Following this grant, he holds 96,899 options, and there were no open‑market purchases or sales reported in this filing.
Traws Pharma, Inc. reported that director Jack E. Stover received a grant of stock options covering 33,435 shares of common stock. The options have an exercise price of $1.6000 per share and were awarded under the company’s 2021 Incentive Compensation Plan. They will vest 100% on the first anniversary of the March 8, 2026 grant date, giving Stover the right to buy the full amount after one year if he chooses to exercise.
Traws Pharma, Inc. reported that Chief Medical Officer Robert Redfield received a grant of stock options covering 108,854 shares of common stock. These options have an exercise price of $1.6000 per share and were awarded under the company’s 2021 Incentive Compensation Plan.
The options will vest 100% on the first anniversary of the March 8, 2026 grant date, and expire on March 8, 2036. Following this award, Redfield holds options for 108,854 underlying shares, reflecting a compensation-related acquisition rather than an open‑market trade.
Traw Pharma, Inc. director Mary Teresa Shoemaker reported a grant of stock options as equity compensation. She received options covering 33,435 shares of common stock with an exercise price of $1.6000 per share, awarded by the company’s compensation committee under its 2021 Incentive Compensation Plan.
The options will vest 100% on the first anniversary of the 2026-03-08 grant date and expire on 2036-03-08. Following this award, Shoemaker holds 33,435 stock options directly.
Traws Pharma, Inc. reported a new equity award to one of its directors. On 12/12/2025, the director acquired 4,058 restricted stock units of common stock at a stated price of $0 per share and was granted 16,234 stock options with a $2.33 exercise price. The restricted stock units will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock. The stock options also vest 100% on the first anniversary of the grant date and are exercisable into 16,234 shares of common stock from 12/12/2026 until their expiration on 12/12/2035.
Traws Pharma director Trafford Clarke reported receiving new equity compensation. On 12/12/2025 he was granted 6,157 restricted stock units at $0 that will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock.
He also received a stock option covering 24,629 shares of Traws Pharma common stock at an exercise price of $2.33 per share, which becomes fully exercisable on 12/12/2026 and expires on 12/12/2035. After these grants, he holds 6,157 restricted stock units and 24,629 stock options, all reported as directly owned.
Traws Pharma, Inc. director Werner Cautreels reported equity awards dated 12/12/2025. He received 4,874 restricted stock units at a price of $0, increasing his directly held common stock to 109,222 shares.
He was also granted stock options for 19,496 shares of common stock at an exercise price of $2.33, expiring 12/12/2035. The restricted stock units and the options each vest 100% on the first anniversary of the grant date.
Traws Pharma, Inc. director Mary Teresa Shoemaker reported equity awards dated 12/12/2025. She received 6,157 restricted stock units of common stock at a reported price of $0, leaving her with 6,292 common shares beneficially owned directly after the transaction. The filing states these restricted stock units will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock. She was also granted a stock option for 24,629 shares of common stock at an exercise price of $2.33 per share, which becomes exercisable on 12/12/2026 and expires on 12/12/2035, and was reported as acquired at a price of $0.
Traws Pharma, Inc. reported an insider equity award for director Jack E. Stover. On 12/12/2025, he received an award of 6,157 restricted stock units. According to the disclosure, these restricted stock units vest 100% on the first anniversary of the grant date, and each unit converts into one share of common stock.
On the same date, Stover was also granted a stock option for 24,629 shares of common stock at an exercise price of $2.33 per share. The option becomes exercisable on 12/12/2026 and expires on 12/12/2035. After these transactions, he beneficially owned 6,165 shares of common stock and 24,629 stock options, all held directly.
Traws Pharma, Inc. reported an insider equity award for its Chief Executive Officer and director, Iain Dukes. On 12/12/2025, he acquired 36,943 shares of common stock at a price of $0 through an award of restricted stock units, bringing his directly held common stock holdings to 171,130 shares. These restricted stock units are scheduled to vest 100% on the first anniversary of the grant date and each unit will convert into one share of common stock.
On the same date, Dukes received a stock option covering 147,771 shares of common stock with an exercise price of $2.33 per share, granted at a price of $0. These options vest 100% on 12/12/2026 and expire on 12/12/2035, and he beneficially owns 147,771 stock options following this grant.
Traws Pharma, Inc. reported that its Chief Science Officer for Virology received new equity awards on December 12, 2025. The filing shows an acquisition of 18,471 shares of common stock, described as restricted stock units that will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock. Following this grant, the officer beneficially owns 115,971 shares of common stock.
The officer was also granted a stock option for 73,886 shares of common stock at an exercise price of $2.33 per share. These options vest 100% on the first anniversary of the grant date, becoming exercisable on December 12, 2026, and expire on December 12, 2035. Both the common stock and the options are held directly.
Traws Pharma, Inc. reported that its Chief Medical Officer, Robert Redfield, received new equity awards in the company’s stock. On 12/12/2025 he acquired 16,419 shares of common stock for $0 as an award of restricted stock units that vest 100% on the first anniversary of the grant date, bringing his directly owned common shares to 113,919.
He was also granted 65,676 stock options with an exercise price of $2.33 per share. These options become exercisable on 12/12/2026, expire on 12/12/2035, and relate to 65,676 shares of common stock. The restricted stock units convert into common stock on a one-for-one basis once vested, tying a portion of his compensation to the company’s share performance.
Traws Pharma director and chief operating officer Nikolay Savchuk reported new equity awards. On 12/12/2025, he received 16,419 restricted stock units of Traws Pharma common stock at $0, increasing his direct holdings to 150,606 shares.
The same day, he was granted stock options to buy 65,676 Traws Pharma shares at an exercise price of $2.33. Both the restricted stock units and the options vest 100% on the first anniversary of the 12/12/2025 grant date, providing additional long-term equity-based compensation.
Traws Pharma, Inc. (TRAW) reported an equity compensation grant to one of its directors, John Leaman. On 11/21/2025, he was granted a stock option to purchase 12,770 shares of Traws Pharma common stock at an exercise price of $2.31 per share. The option is held directly and expires on 11/21/2035.
The option vests over three years from the grant date, with 33% vesting on the first anniversary, 33% on the second anniversary, and the remaining 34% on the third anniversary. Following this grant, John Leaman beneficially owns 12,770 derivative securities in the form of these stock options.
Traws Pharma (TRAW) reported an insider equity award. Chief Science Officer, Virology, Charles David Pauza acquired 32,406 stock options at an exercise price of $3.01 on 10/12/2025, as disclosed on Form 4.
The options vest 100% on 10/12/2026 and expire on 10/12/2035. Following the transaction, the reporting person beneficially owns 32,406 derivative securities directly. This reflects routine equity compensation.
Traws Pharma (TRAW) reported an insider equity award. Chief Operating Officer and Director Nikolay Savchuk was granted a stock option for 22,435 shares at an exercise price of $3.01 on 10/12/2025.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. The filing lists the holdings as Direct (D). This is a routine compensatory grant disclosed on Form 4.
Traws Pharma (TRAW) reported an insider equity award. The company’s Chief Medical Officer filed a Form 4 disclosing a grant of 32,406 stock options on 10/12/2025 with an exercise price of $3.01 per share. The options vest 100% on the first anniversary of the grant date (10/12/2026) and carry an expiration date of 10/12/2035. The filing lists 32,406 derivative securities beneficially owned following the transaction, held under direct ownership.
Traws Pharma (TRAW) reported an insider equity grant. CEO and Director Iain Dukes received a stock option for 64,839 shares at an exercise price of $3.01 on 10/12/2025.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. Following the grant, 64,839 derivative securities were beneficially owned, held directly. The filing reflects a routine equity compensation award.
Traws Pharma, Inc. (TRAW) filed a Form 4 disclosing a director stock option grant. On 10/12/2025, the reporting person acquired 11,530 stock options at a $3.01 exercise price. The options vest 100% on the first anniversary of the grant date and expire on 10/12/2035. Following the transaction, 11,530 derivative securities were beneficially owned on a direct basis.
Traws Pharma (TRAW) disclosed a Form 4 showing a director received a stock option grant. The award covers 11,530 options with an exercise price of $3.01 per share, granted on October 12, 2025.
The options vest 100% on the first anniversary of the grant date and become exercisable on October 12, 2026, with an expiration on October 12, 2035. Following the transaction, the reporting person held 11,530 derivative securities, reported as Direct (D) ownership.
Traws Pharma, Inc. filed a Form 4 reporting a director stock option grant. On 10/12/2025, the reporting person received a stock option to purchase 11,530 shares of common stock at an exercise price of $3.01 per share.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. Following this grant, 11,530 derivative securities were beneficially owned on a direct basis. The filing lists no transactions in non-derivative common stock.
Traws Pharma (TRAW) reported a director stock option grant on 10/12/2025. The filing shows a grant of 11,530 stock options with an exercise price of $3.01 per share. The options vest 100% on 10/12/2026 and expire on 10/12/2035.
Following the transaction, the reporting person held 11,530 derivative securities, with ownership listed as Direct. This was a routine equity award; no common shares were listed in the non-derivative table.
Traws Pharma (TRAW) reported an insider equity award. On 10/01/2025, a company director received a stock option grant covering 15,609 shares of common stock at an exercise price of $1.89 per share.
The options expire on 10/01/2035 and were reported with a derivative security price of $0. The award vests over three years from the grant date: 33% on the first anniversary, 33% on the second, and 34% on the third. The filing lists direct (D) ownership following the transaction.